FAM13B

Across TCGA pan-cancer cohorts, FAM13B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FAM13B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FAM13B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM13B expression acts as an unfavorable survival marker.

STAD, SCLC, and COAD are the cancer types where FAM13B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.199	0.730	.002	12	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	12	view →
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	All	0.188	0.687	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	All	0.192	0.724	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FAM13B–STAD (OS)

Open the STAD breakdown →